In preclinical models of pulmonary atrial hypertension (PAH), an sGC stimulator reduced pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling in chronic hypoxic models of PAH, and reversed hemodynamic and structural changes in rats with severe pulmonary hypertension. This evidence concerns the gene SGCB and pulmonary hypertension.